TY - JOUR
T1 - Time in LDL cholesterol target range and major adverse cardiovascular events risk: A pooled analysis of two cohorts
AU - Liu, Yezhou
AU - Lv, Zhe
AU - Yan, Hong
AU - Liu, Yamei
AU - Zhang, Jiaheng
AU - Bian, Wenming
AU - Liu, Yetong
AU - Song, Zhaojie
AU - Han, Peng
AU - Chen, Tao
AU - Li, Chao
N1 - Publisher Copyright:
© 2025
PY - 2025/9/10
Y1 - 2025/9/10
N2 - Background: Traditional management of low-density lipoprotein cholesterol (LDL-C) relies on single-point measurements, neglecting long-term magnitude and the duration of exposure to elevated LDL-C over time. This study aimed to evaluate the association between LDL-C time in target range (TTR) and the risk of major adverse cardiovascular events (MACE) in two US cohorts. Methods: This study was a secondary analysis of the Atherosclerosis Risk in Communities (ARIC) study and the Multi-Ethnic Study of Atherosclerosis (MESA) cohorts. LDL-C TTR was defined as the percentage of the area under curve for LDL-C values below 100 mg/dL relative to the total area over the first 4 visits. Association between LDL-C TTR and MACE was estimated using adjusted Cox models and Fine-Gray competing risk models. Results: Over a mean follow-up of 21.2 ± 8.1 years, 3306 MACE occurred among 16,310 participants. The highest LDL-C TTR quartile was associated with a 25 % reduction in MACE (HR: 0.75, 95 % CI: 0.68 to 0.83), 42 % reduction in myocardial infarction (HR: 0.58, 95 % CI: 0.49 to 0.68), 24 % reduction in stroke (HR: 0.76, 95 % CI: 0.64 to 0.91), and 13 % reduction in CVD death (HR: 0.87, 95 % CI: 0.76 to 1.00; borderline significance). TTR remained significantly associated with MACE after adjusting for mean LDL-C or LDL-C variability, and were robust in competing risk analyses. TTR also outperformed mean LDL-C and LDL-C variability in prognostic value (Akaike information criterion, C-statistics). Conclusions: LDL-C TTR independently predicts MACE and may offer a more comprehensive assessment of long-term LDL-C control than mean levels or variability, supporting its potential clinical utility.
AB - Background: Traditional management of low-density lipoprotein cholesterol (LDL-C) relies on single-point measurements, neglecting long-term magnitude and the duration of exposure to elevated LDL-C over time. This study aimed to evaluate the association between LDL-C time in target range (TTR) and the risk of major adverse cardiovascular events (MACE) in two US cohorts. Methods: This study was a secondary analysis of the Atherosclerosis Risk in Communities (ARIC) study and the Multi-Ethnic Study of Atherosclerosis (MESA) cohorts. LDL-C TTR was defined as the percentage of the area under curve for LDL-C values below 100 mg/dL relative to the total area over the first 4 visits. Association between LDL-C TTR and MACE was estimated using adjusted Cox models and Fine-Gray competing risk models. Results: Over a mean follow-up of 21.2 ± 8.1 years, 3306 MACE occurred among 16,310 participants. The highest LDL-C TTR quartile was associated with a 25 % reduction in MACE (HR: 0.75, 95 % CI: 0.68 to 0.83), 42 % reduction in myocardial infarction (HR: 0.58, 95 % CI: 0.49 to 0.68), 24 % reduction in stroke (HR: 0.76, 95 % CI: 0.64 to 0.91), and 13 % reduction in CVD death (HR: 0.87, 95 % CI: 0.76 to 1.00; borderline significance). TTR remained significantly associated with MACE after adjusting for mean LDL-C or LDL-C variability, and were robust in competing risk analyses. TTR also outperformed mean LDL-C and LDL-C variability in prognostic value (Akaike information criterion, C-statistics). Conclusions: LDL-C TTR independently predicts MACE and may offer a more comprehensive assessment of long-term LDL-C control than mean levels or variability, supporting its potential clinical utility.
KW - Cardiovascular death
KW - Low-density lipoprotein
KW - Major adverse cardiovascular events
KW - Myocardial infarction
KW - Stroke
KW - Time in target range
U2 - 10.1016/j.ajpc.2025.101290
DO - 10.1016/j.ajpc.2025.101290
M3 - Article
AN - SCOPUS:105015649434
SN - 2666-6677
VL - 24
JO - American Journal of Preventive Cardiology
JF - American Journal of Preventive Cardiology
M1 - 101290
ER -